Purpose Diabetic maculopathy can be treated with intravitreal injection of vascular
endothelial growth factor (VEGF) inhibitors. However, the therapy is not effective in all …

Purpose: Treatment of diabetic maculopathy with vascular endothelial growth factor
inhibitors is in some patients ineffective, and, therefore, parameters predicting visual …

Purpose: To evaluate macular morphology and function in diabetic macular edema (DME)
over the course of intravitreal anti‐vascular endothelial growth factor (VEGF) treatment with …

Purpose To investigate central subfield thickness (CST) nonimprovers' anatomic response in
macular areas outside the central subfield and the time course of this response …

Purpose: To identify baseline optical coherence tomography morphologic characteristics
predicting the visual response to anti-vascular endothelial growth factor therapy in diabetic …

Purpose Diabetic macular edema (DME) is a leading cause of vision loss in diabetics. Anti–
vascular endothelial growth factor (VEGF) therapy has been shown to be an effective …

Background Macular contraction after anti-vascular endothelial growth factor (anti-VEGF)
injections for diabetic macular edema (DME) was evaluated by documenting the …

Purpose To investigate the correlation of retinal thickness measured with SD OCT and visual
acuity in eyes with diabetic macular edema (DME) before and after intravitreal injection of …

Objective: To examine the relationship between early response to anti-vascular endothelial
growth factor (VEGF) treatment and visual prognosis. Methods: We retrospectively separated …

Objective This study was designed to evaluate the correlation of baseline visual acuity (VA)
with VA outcome in response to anti-vascular endothelial growth factor (VEGF) in diabetic …